Many GLP-1 Drug Problems
GLP-1 Drug Problems and How Often They Occur (2026)
The most common problem with GLP-1 drugs is gastrointestinal (GI) upset: about 3 in 4 people on semaglutide 2.4 mg report GI symptoms, compared with about half on placebo.[1][2] Serious problems are much rarer. Gallbladder disease, pancreatitis, retinopathy worsening and NAION each affect from under 1% to a few percent of users, or fewer than 1 in 10,000 for NAION. The biggest practical problems are tolerability, lean-mass loss and weight regain after stopping.
TL;DR
- Common and expected: In the Wegovy label, 73% of semaglutide 2.4 mg users had GI adverse reactions vs 47% on placebo (nausea 44% vs 16%).[1][2] Tirzepatide's rate is similar (56% vs 30%).[3][4][5] These symptoms drive treatment discontinuation of about 6–17% on drug vs 3–8% on placebo.[2][6][7][8][9]
- Real but uncommon serious risks: These include gallbladder disease (RR 1.37 across 76 RCTs), worsening of existing diabetic retinopathy (3.0% vs 1.8% in SUSTAIN-6)[10][11][12] and NAION (rated "very rare", ≤1 in 10,000, by EMA).[13] Pancreatitis, gastroparesis and bowel obstruction show signals only in observational studies, and randomized trials don't show a clear excess.[14][15]
- Signals that have mostly been reassured away: Suicidality was cleared after FDA's 91-trial analysis.[16][17] Human thyroid cancer data are mixed but mostly null (HR 0.93 in a Scandinavian cohort).[18] Aspiration under anesthesia remains debated because retained gastric content clearly rises but aspiration events don't consistently increase.[19][20][21]
Key Findings
- Tolerability is the real-world limiting factor. GI events cluster during dose escalation and are dose-dependent.[5][22] Triple and amylin combinations are at least as GI-heavy: CagriSema caused nausea in 55% of users, and retatrutide 12 mg caused nausea in about 42–43%.[23][24][25][26]
- Most "serious" risks have small absolute effects. For gallbladder disease, He and colleagues' 2022 JAMA Internal Medicine meta-analysis (76 RCTs, 103,371 patients) reported "an additional 27 cases per 10,000 persons treated per year." For NAION, the EMA's safety committee (PRAC) said in June 2025 that this "corresponds to approximately one additional case of NAION per 10,000 person-years of treatment."
- Quality of weight loss and what happens afterwards matter as much as side effects. About 25% of weight lost on tirzepatide was lean mass in the SURMOUNT-1 DXA substudy ("about 75% of the weight lost was fat and 25% was lean mass"), versus a reported 38–45% for semaglutide in STEP 1. In the STEP 1 extension (Wilding et al., Diabetes Obes Metab 2022, n=327), "participants regained two-thirds of their prior weight loss" within a year of stopping semaglutide.
- A new agent-specific signal is dysesthesia (abnormal skin sensation) with retatrutide. It affected up to 20.9% of users at 12 mg in TRIUMPH-4, vs 0.7% on placebo.[25][27]
Table 1. Common problems (gastrointestinal and tolerability)
| Problem | Incidence on drug | Incidence placebo | Relative risk / notes | Drug(s) studied | Refs |
|---|---|---|---|---|---|
| Any GI adverse reaction | 73% | 47% | Severe GI 4.1% vs 0.9%[1][2] | Semaglutide 2.4 mg | Wegovy label 2026 Wegovy label 2025 |
| Any GI adverse reaction | 56% at each dose | 30% | Mostly during dose escalation[3][4][5] | Tirzepatide 5–15 mg | Zepbound label |
| Nausea | 44% | 16% | About 2.8× placebo; mostly mild to moderate[1][2][5] | Semaglutide 2.4 mg | Wegovy label 2025 |
| Nausea | ≈24–33% | ≈8–10% | Dose-related[28][29][30] | Tirzepatide 5–15 mg | Zepbound label SURMOUNT-1 summary |
| Vomiting | 25% | 6% | About 4× placebo[1][2] | Semaglutide 2.4 mg | Wegovy label 2025 |
| Diarrhea | 30% | 16% | About 2× placebo[1][2] | Semaglutide 2.4 mg | Wegovy label 2025 |
| Constipation | 23.4% | 9.5% | STEP 1, 68 weeks[31] | Semaglutide 2.4 mg | STEP 1 CT.gov |
| Dyspepsia | 10.3% | 3.5% | Eructation 8.6% vs 0.5%[31] | Semaglutide 2.4 mg | STEP 1 CT.gov |
| GERD | 9.9% | 4.0% | STEP 5, 104 weeks[32] | Semaglutide 2.4 mg | STEP 5 CT.gov |
| Abdominal pain | 13.0% | 4.9% | STEP 3 | Semaglutide 2.4 mg | STEP 3 CT.gov |
| Discontinuation due to AEs | 6.8% | 3.2% | Mainly nausea 1.8% and vomiting 1.2%[2][6] | Semaglutide 2.4 mg | Wegovy DailyMed |
| Discontinuation due to AEs | 16.6% | 8.2% | SELECT, 3.3-year median; GI 10.0% vs 2.0%[15][33][34] | Semaglutide 2.4 mg | SELECT safety TCTMD SELECT |
| Discontinuation due to AEs | 4–10.5% | 2.1–4% | Across SURMOUNT trials[35] | Tirzepatide | Tirzepatide review |
| Injection-site reactions | 6–8% | 2% | More frequent with anti-drug antibodies[28][36] | Tirzepatide | Zepbound label 2026 |
| Hair loss (alopecia) | 3.3% | 1% | Women 4% vs men 0.9%; 5.8% at 7.2 mg[2][37] | Semaglutide 2.4 mg | Wegovy label 2026 |
| Hair loss (alopecia) | ≈4–5% | ≈1% | Listed among ≥5% reactions[28][36][38][39] | Tirzepatide | Zepbound label |
| Hypotension | 1.3% | 0.4% | Syncope 0.8% vs 0.2%[2][6][40] | Semaglutide 2.4 mg | Wegovy DailyMed |
| Hypotension | 1.6% | 0.1% | Volume loss from GI events[41] | Tirzepatide | Zepbound FDA SPL |
| Increased heart rate | +1 to 4 bpm mean | Not reported | Adolescents: ≥20 bpm rise in 54% vs 39%[2][6][40][42] | Semaglutide 2.4 mg | Wegovy label 2026 |
Table 2. Serious, rare or debated problems
| Problem | Incidence on drug | Incidence on placebo | Relative risk / notes | Drug(s) studied | Refs |
|---|---|---|---|---|---|
| Gallbladder/biliary disease | RR 1.37 overall | Placebo or active | RR 2.29 in weight-loss trials; 27 extra cases per 10,000 per year (He, JAMA IM 2022); meta-analysis of 76 RCTs | GLP-1 RA class | He JAMA IM 2022 Gallbladder review |
| Gallbladder disorders | 2.8% | 2.3% | p=0.04; cholelithiasis 1.4% vs 1.1%[43] | Semaglutide 2.4 mg | SELECT safety |
| Cholecystitis | 0.7% | 0.2% | Cholelithiasis 1.1% vs 1%; cholecystectomy 0.2% vs 0%[41][44] | Tirzepatide | Zepbound label |
| Acute pancreatitis (RCT) | 0.2% | 0.3% | No excess in SELECT[9][15] | Semaglutide 2.4 mg | NERDCAT SELECT |
| Acute pancreatitis (observational) | 4.6–7.9 per 1,000 PY | 1.0 per 1,000 PY | HR 9.09 (95% CI 1.25–66.0); very imprecise[45][46] | Semaglutide, liraglutide vs bupropion-naltrexone | TCTMD Sodhi Endocrinology Advisor |
| Gastroparesis | 7.3–9.1 per 1,000 PY | 3.1 per 1,000 PY | HR 3.67 (1.15–11.9); observational[45][46] | Semaglutide, liraglutide | TCTMD Sodhi |
| Bowel obstruction | 0–8.1 per 1,000 PY | 1.7 per 1,000 PY | HR 4.22 (1.02–17.4); observational[45] | Semaglutide, liraglutide | Endocrinology Advisor |
| Retained gastric content at anesthesia | OR 5.96 vs non-users | Non-users | Low-certainty evidence; holding ≥1 dose gave OR 0.51[20][47] | GLP-1 RA class | Elkin Anaesthesia 2025 |
| Pulmonary aspiration | Conflicting | Non-users | Endoscopy meta-analysis OR 2.29 (1.36–3.87); another OR 1.23, not significant[19][48] | GLP-1 RA class | Endoscopy meta 2025 Endoscopy meta 2 |
| Hypoglycemia with sulfonylurea | Severe 0.8–1.2% | Not reported | Documented symptomatic 17.3–24.4%[12][49] | Semaglutide 0.5–1 mg | Ozempic label 2026 |
| Hypoglycemia with insulin | Severe 0–1.5%; <54 mg/dL 13–19% | Severe 0%; <54 mg/dL 13% | SURPASS-5 and SUSTAIN-5[12][50] | Tirzepatide, semaglutide | Mounjaro label Ozempic label 2026 |
| Hypoglycemia, T2D on weight dose | 6.2% (<54 mg/dL) | 2.5% | Higher risk with sulfonylurea[2] | Semaglutide 2.4 mg | Wegovy label 2026 |
| Acute kidney injury | Not increased | Similar | SELECT showed no AKI excess; label warns about dehydration[2][9][34] | Semaglutide 2.4 mg | Cleveland Clinic SELECT |
| Diabetic retinopathy complications | 3.0% | 1.8% | HR 1.76 (1.11–2.78); 84% had pre-existing DR[10][51] | Semaglutide 0.5–1 mg | SUSTAIN-6 NEJM |
| Diabetic retinopathy (meta-analysis) | RR 1.20 | Comparators | 95% CI 0.99–1.47; borderline[52] | Semaglutide | AAO statement |
| NAION | ≤1 per 10,000 users | Not reported | EMA "very rare"; observational studies about 2× risk[13][53] | Semaglutide | WHO alert AAO NAION 2026 |
| NAION (RCT pool) | 15 probable events | 134,253 participants | FDA required a class-wide warning in Nov 2026[54] | All GLP-1 RAs | Pharmacally FDA |
| Thyroid cancer, all types | HR 0.93 | DPP-4 inhibitor users | 95% CI 0.66–1.31; Scandinavian cohort of 145,410[18][55] | Liraglutide, semaglutide | Pasternak BMJ 2024 |
| Medullary thyroid cancer | HR 1.19 | DPP-4 inhibitor users | CI 0.37–3.86; French study HR 1.78 (1.04–3.05)[18][56] | GLP-1 RA class | Pasternak BMJ 2024 |
| Suicidal ideation/behavior | No increase | Placebo | FDA analysis of 91 RCTs (n=107,910); warning removal requested[16][17] | Liraglutide, semaglutide, tirzepatide | Pharmacy Times FDA HCPLive FDA |
| Suicidality (observational) | RR 0.57 | Other antidiabetics | 95% CI 0.08–4.21; not significant[57] | GLP-1 RA class | Padhi meta 2025 |
| Hypersensitivity | 5% | 3% | Severe 0.1% vs 0%; anaphylaxis seen postmarketing[28][36] | Tirzepatide | Zepbound label |
| Lean mass loss | ≈38–45% of weight lost | Not reported | Lean mass −9.7% (Wilding, STEP 1 DXA); share reported variously as 38%, 39.7% or 45% | Semaglutide 2.4 mg | Healio lean mass DDT lean mass |
| Lean mass loss | ≈25% of weight lost | ≈25% on placebo | Lean mass −10.9%,[58] fat −33.9% (SURMOUNT-1 DXA, n=160) | Tirzepatide | Healio lean mass |
| Bone density loss | Not quantified | Not reported | Human data largely neutral[59] | GLP-1 RA class | BMD pilot trial |
| Nutritional deficiency | 12.7% at 6 mo; 22.4% at 12 mo | Metformin-only users lower | Vitamin D deficiency 7.5% then 13.6%; claims data, n=461,382[60][61] | GLP-1 RA class | Butsch Obesity Pillars |
| Weight regain after stopping | ≈2/3 of lost weight in 1 year | Placebo regained 1.9 points | Regained 11.6 of 17.3 percentage points[62][63] (Wilding, STEP 1 extension, n=327) | Semaglutide 2.4 mg | STEP 1 extension |
| Weight regain after stopping | +14.0% body weight | −5.5% if continued | SURMOUNT-4, 52 weeks[64] | Tirzepatide | Weight regain review |
| Compounded dosing errors | 5–20× intended dose | Not reported | Some cases hospitalized; mg-to-units confusion[65][66][67] | Compounded semaglutide | FDA alert 2024 |
| Poison center exposures | 22,966 cases, 2019–2025[68] | Not reported | ≈1,500% rise in calls since 2019[68][69] | GLP-1 RA class | America's Poison Centers |
| "Ozempic face" / skin laxity | Not quantified | Not reported | Consequence of rapid fat loss; no trial incidence | GLP-1 RA class | Not reported |
Table 3. Newer agents (phase 3 data)
| Problem | Incidence on drug | Incidence placebo | Relative risk / notes | Drug(s) studied | Refs |
|---|---|---|---|---|---|
| Nausea | 28.6% / 38.4% / 42.4% | 14.8% | TRIUMPH-1 at 4/9/12 mg[23][24] | Retatrutide | Lilly TRIUMPH-1 AJMC TRIUMPH-1 |
| Dysesthesia | 5.1% / 12.3% / 12.5% | 0.9% | TRIUMPH-4 at 12 mg: 20.9% vs 0.7%[23][25] | Retatrutide | Lilly TRIUMPH-1 Retatrutide safety |
| Discontinuation due to AEs | 4.1% / 6.9% / 11.3% | 4.9% | TRIUMPH-4 at 12 mg: 18.2% vs 4.0%[24][25] | Retatrutide | AJMC TRIUMPH-1 |
| Nausea | 33.7% at 36 mg | ≈12% | ATTAIN-1 | Orforglipron | GI review PMC |
| Discontinuation due to AEs | 5.3–10.3% | 2.7% | 5 mild pancreatitis cases, all on drug[7][70] | Orforglipron | ATTAIN-1 NEJM Diabetes Distilled |
| Any GI adverse event | 79.6% | 39.9% | Nausea 55% vs 12.6%; vomiting 26.1% vs 4.1%[26][71] | CagriSema | Novo REDEFINE 1 |
| Discontinuation due to AEs | 5.9% | 3.5% | REDEFINE 2: 8.4% vs 3%[72][73] | CagriSema | Novo FDA filing |
Caveats
- Trial rates vs real-world rates: Trials use slow dose escalation and exclude high-risk patients. Real-world GI rates and discontinuation are likely higher. In SELECT, discontinuation over 3+ years was more than double the 68-week label figure.[2][8]
- Observational signals are imprecise: The pancreatitis HR of 9.09 has a 95% CI of 1.25–66.0.[74] The Sodhi cohort had only 613 semaglutide users and an active comparator (bupropion-naltrexone),[14] which may itself lower GI risk. Large RCTs such as SELECT found no pancreatitis excess (0.2% vs 0.3%).[15]
- NAION: The FDA class-wide warning (Nov 2026) is reported here through a trade-press summary, not the FDA document itself.[54] Within the RCT data, the evidence rests on very few events.[54]
- Lean mass is not the same as muscle: DXA "lean mass" includes water and organs. In SURMOUNT-1, the lean share of weight lost was similar on placebo, which suggests this is largely a weight-loss effect rather than a drug-specific one.[58][75]
- Nutritional deficiency data: These come from claims coding. Patients who saw a dietitian were diagnosed more often, so detection bias is likely, and causality is not established.[61][76][77]
- Gaps: Drug-specific incidence for liraglutide, dulaglutide and exenatide was not separately tabulated here. Their GI profile is broadly similar to the class, and liraglutide appears in the Sodhi cohort.[14] No validated incidence exists for "Ozempic face" or for bone loss.
Recommendations
- Expect and manage GI effects: escalate doses slowly and eat smaller meals.[78] Treat persistent severe vomiting as a dehydration and kidney risk.[2]
- Before starting, check retinal status in people with diabetes and existing retinopathy. Lower sulfonylurea or insulin doses to avoid hypoglycemia.[12][79]
- Protect lean mass with resistance training and adequate protein.[80] Consider vitamin D and micronutrient checks at 6–12 months.[61]
- Before procedures with sedation, tell the anesthetist or endoscopist about GLP-1 use.[2] Holding at least one dose or following a liquid diet reduces retained gastric content.[20][81]
- Plan for long-term use or a structured exit, because stopping typically reverses about two-thirds of the weight lost within a year.[62]
- Avoid compounded products when possible. If you use them, confirm the dose in both mg and units with the pharmacist, because 5–20× overdoses have been reported.[67][68]
Sources:
- Wegovy label 2026
- Wegovy label 2026 s033
- Wegovy label 2025
- Wegovy DailyMed
- Zepbound label 2024
- Zepbound label 2026
- Zepbound label Lilly
- Zepbound FDA SPL
- Ozempic label 2026
- Mounjaro label
- STEP 1 CT.gov
- STEP 3 CT.gov
- STEP 5 CT.gov
- SURMOUNT-1 summary
- Tirzepatide review
- SELECT safety PubMed
- SELECT safety abstract
- TCTMD SELECT
- NERDCAT SELECT
- Cleveland Clinic SELECT
- He JAMA IM 2022
- Gallbladder review
- TCTMD Sodhi
- Endocrinology Advisor
- Elkin Anaesthesia 2025
- Endoscopy meta 2025
- Endoscopy meta 2
- SUSTAIN-6 NEJM
- AAO statement
- WHO alert
- AAO NAION 2026
- Pharmacally FDA
- Pasternak BMJ 2024
- Pharmacy Times FDA
- HCPLive FDA
- Padhi meta 2025
- Healio lean mass
- DDT lean mass
- BMD pilot trial
- Butsch Obesity Pillars
- STEP 1 extension
- Weight regain review
- FDA alert 2024
- America's Poison Centers
- Lilly TRIUMPH-1
- AJMC TRIUMPH-1
- Retatrutide safety
- GI review PMC
- ATTAIN-1 NEJM
- Diabetes Distilled
- Novo REDEFINE 1
- Novo FDA filing
Sources
- HIGHLIGHTS OF PRESCRIBING INFORMATION
- HIGHLIGHTS OF PRESCRIBING INFORMATION
- Highlights of Prescribing Information - accessdata.fda.gov
- Zepbound Injection, Solution - FDA Label NDC 0002-2471
- GLP-1 Side Effects by Week: What's Normal, What's Not
- Label: Wegovy- semaglutide injection, solution - DailyMed - NIH
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
- Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial - PubMed
- International Clinical Trial Finds that Semaglutide Reduced Cardiovascular Events by 20% in Adults with Overweight or Obesity Who Don’t Have Diabetes
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- GLP-1 receptor agonists linked to increased risk of gallbladder, biliary diseases
- highlights of prescribing information - accessdata.fda.gov
- The use of semaglutide medicines and risk of non-arteritic anterior ischemic optic neuropathy (NAION)
- GI Adverse Events Increased With Use of GLP-1 Agonists for Weight Loss
- SELECT: Semaglutide in patients with CV disease & overweight/obesity — NERDCAT
- FDA Finds No Increased Suicide Risk With GLP-1 Medications, Requests Removal of Warning Labels
- FDA Requests Removal of Suicidal Ideation and Behavior Warning From GLP-1 RA Therapies
- Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study
- Glucagon-like peptide-1 receptor agonists increase the risk of residual gastric content and pulmonary aspiration on upper endoscopy: A meta-analysis - PubMed
- Association between glucagon‐like peptide‐1 receptor agonist use and peri‐operative pulmonary aspiration: a systematic review and meta‐analysis - Elkin - 2025 - Anaesthesia - Wiley Online Library
- Association Between Glucagon-like Peptide-1 Receptor Agonist Use and Perioperative Aspiration: A Systematic Review and Meta-Analysis
- Tirzepatide Side Effects: Nausea, Diarrhea, Rates by Dose & Management (2026)
- Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial
- Retatrutide Achieves Up to 30.3% Average Weight Loss in Phase 3 TRIUMPH-1 Trial
- Retatrutide Side Effects and Safety: What the Phase 3 Data Actually Shows (2026)
- Novo's CagriSema was associated with 25% mean weight loss among early responders in a post hoc analysis of REDEFINE 1 presented at ObesityWeek® 2026
- Retatrutide Side Effects: Phase 3 Trial Data
- Zepbound Side Effects: Full Breakdown by Frequency
- Tirzepatide before and after: what the trials actually show
- SURMOUNT-1 Trial Results: Tirzepatide Weight Loss Study Explained
- STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
- Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
- Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics
- First study with positive cardiovascular outcome in obesity: Reflections on SELECT
- Full article: Tirzepatide for overweight and obesity management
- These highlights do not include all the information needed to use ZEPBOUND safely and effectively. See full prescribing information for ZEPBOUND.ZEPBOUND® (tirzepatide) Injection, for subcutaneous useInitial U.S. Approval: 2022
- Do GLP-1s Cause Hair Loss? FDA Label Rates
- GLP-1 Hair Loss: Why It Happens and How Long It Lasts
- Tirzepatide and Semaglutide Hair Loss
- Wegovy: Package Insert / Prescribing Information / MOA
- These highlights do not include all the information needed to use ZEPBOUND safely and effectively. See full prescribing information for ZEPBOUND.<br/>ZEPBOUND™ (tirzepatide) Injection, for subcutaneous use<br/>Initial U.S. Approval: 2022
- HIGHLIGHTS OF PRESCRIBING INFORMATION These ...
- "Safety profile of semaglutide versus placebo in the SELECT study: a ra" by Robert F. Kushner, Donna H. Ryan et al.
- ZEPBOUND (tirzepatide) injection - accessdata.fda.gov
- GLP-1 Agonist Use for Weight Loss Linked to Gastrointestinal Adverse Events - Endocrinology Advisor
- Major GI Events Rare but Real in Weight-Loss Patients on GLP-1 Drugs
- Association Between Glucagon-like Peptide-1 Receptor Agonist Use and Perioperative Aspiration: A Systematic Review and Meta-Analysis
- GLP-1 Agonists and the Risk of Pulmonary Aspiration during Elective Upper Endoscopy: A Systematic Review and Meta-analysis
- DailyMed - OZEMPIC- semaglutide injection, solution
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215866s031lbl.pdf
- SUSTAIN-6 - subcutaneous semaglutide and cardiovascular outcomes in type 2 Diabetes
- Glucagon-Like Peptide-1 Receptor Agonists and Diabetic Retinopathy: A Statement from the American Academy of Ophthalmology - American Academy of Ophthalmology
- Glucagon-Like Peptide-1 Receptor Agonists
- FDA Requires Class-Wide NAION Warning for GLP-1 Drugs - Pharmacally
- Understanding the Ozempic Thyroid Cancer Warning and What It Means for Patients
- Semaglutide and Thyroid: What to Know
- Association of GLP‐1 Receptor Agonists With Risk of Suicidal Ideation and Behaviour: A Systematic Review and Meta‐Analysis - PMC
- GLP-1 Muscle Loss: How Much Is Muscle and How to Measure It
- Bone mineral density and turnover response to GLP-1 receptor agonists in older adults with overweight/obesity and prediabetes/type 2 diabetes: a 20-week pilot trial post hoc analysis
- What Nutrients Are GLP-1 Users Lacking?
- Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists: A retrospective observational study - ScienceDirect
- Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
- Weight Regain After Stopping a GLP-1: What the Studies Show
- Stopping a GLP-1 medicine: how much weight comes back in the STEP 1 extension and SURMOUNT-4 trials
- Compounded Semaglutide Side Effects: What to Expect
- GLP-1 Overdose: Dosing Errors and FDA Alerts
- FDA alerts health care providers, compounders of dosing errors
- Glucagon-like Peptide-1 (GLP-1) Agonists
- America's Poison Centers - Track Emerging Hazards
- Diabetes Distilled: New oral GLP-1 RA, orforglipron, achieves up to 11.2% mean weight loss - DiabetesontheNet
- What Is CagriSema? Trial Results, Muscle Data & Safety
- News Details
- Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management
- GLP-1 Gastroparesis Risk 2026: Causes, Prevention & When to Worry
- GLP-1 Muscle Preservation Protocol: Fighting Lean Mass Loss
- GLP-1 Agonists Linked to Increased Nutritional Deficiencies, Reveals Research
- GLP-1 Nutritional Deficiencies: What Research Shows
- A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)
- Label: OZEMPIC- semaglutide injection, solution - DailyMed
- Why you should not skip tailored exercise interventions when using incretin mimetics for weight loss
- The role of GLP-1 agonists in perioperative care: a suspension dilemma
Related in VitaminDWiki
- GLP-1 - loses vitamins B1, B12, C, D, as well as muscle and weight
- GLP-1- NOT use just before or while pregnant - lack of safety data Nov 2026
- GLP-1 for weight loss causes increased hair loss in >30 % of the patients
- GLP-1 and pediatric weight loss and regain after stopping - many unknowns
- >200,000 doctors paid by Big Pharma to promote GLP-1, blood thinners, etc.
- Most GLP-1 users are Vitamin D deficient before they start — 4 reasons to supplement
- Ozempic's (GLP-1) depravity is worse than COVID vaccines - 2025
- GLP-1 use for weight loss increases the suicide rate by 150%
- 40% of weight loss from GLP-1 is from muscle loss (not so if lose weight with Vitamin D)
- GLP-1 results in fat loss in your face, making you look older
- The Potential Synergy Between Vitamin D and GLP-1 Medications for Enhanced Weight Loss
Weight Loss and Vitamin D, etc,
- Weight loss and Vitamin D - many studies
- More Weight loss if you add Vitamin D and Receptor activators: Berberine, Butyrate, etc
- Vitamin D, Omega-3, Butyrate etc., should help if taking GLP-1 for weight loss
- Why vitamin D is not advertised for weight loss - it was patented
- Weight loss and Vitamin D, Calcium, and Magnesium
- Weight loss on low-calorie diet: 7 lbs more lost if got lots of Vitamin D
- Omega-3 may reduce weight gain and maintain weight loss
- The Vitamin That Quadruples Weight Loss
- How might Calcium and Vitamin D cause weight loss
- Weight loss improves both vitamin D and insulin resistance